Aclarion (NASDAQ:ACON) CEO Brent Ness joins Natalie Stoberman from the Proactive studio to share how the company utilizes augmented intelligence to treat chronic low back pain.
Aclarion (NASDAQ:ACON)'s innovative approach provides a less invasive way to pinpoint pain and offers promising results. The company's growth includes developing strong foundational technology, collaborating with key opinion leaders, and building compelling evidence through clinical trials and economic value analyses.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy, proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to non-invasively help physicians distinguish between painful and non-painful discs in the lumbar spine.